13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study (Q41382795)
Jump to navigation
Jump to search
scientific article published on 23 March 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | 13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study |
scientific article published on 23 March 2015 |
Statements
1 reference
13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study (English)
1 reference
Natasha Halasa
1 reference
William C Gruber
1 reference
Mariane De Montalembert
1 reference
Miguel R Abboud
1 reference
Anne Fiquet
1 reference
Adlette Inati
1 reference
Jeffrey D Lebensburger
1 reference
Normeen Kaddah
1 reference
Galila Mokhtar
1 reference
Antonio Piga
1 reference
David C Rees
1 reference
Paul Telfer
1 reference
Catherine Driscoll
1 reference
Sami Al Hajjar
1 reference
Qin Jiang
1 reference
Emilio A Emini
1 reference
Alejandra Gurtman
1 reference
Daniel A Scott
1 reference
23 March 2015
1 reference
1 reference
62
1 reference
8
1 reference
1427-1436
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference